Management Team

Dr Gisela Mautner 

Chief Executive Officer and Managing Director

MD-PhD (TU-LMU Munich), MPH (Harvard), MBA (Kellogg), FACPE (Australia)

Dr Mautner has more than 20 years of extensive leadership experience in global pharmaceutical organisations, including operational, medical and scientific advisory roles across multiple therapeutic areas. During her career she held senior positions at global pharmaceutical companies like MSD (Merck), Bayer and Amgen in Germany as well as Australia.

Dr Mautner holds a Doctor of Medicine degree and a PhD from Germany, a Master of Public Health (MPH) from Harvard University, and a Master of Business Administration (MBA) from Northwestern University of Chicago.

Dr Mautner was appointed Chief Executive Officer and Managing Director of Noxopharm in 2022, previously serving as Chief Medical Officer since 2019.

Read more

Jeanette Bell 

Chief Operating Officer

BMedSc, MScM, PhD

Jeanette joined Noxopharm in 2019, with over 30 years’ experience in the private, public and corporate healthcare sectors. This included 15 years with Lilly Pharmaceuticals in positions spanning Clinical Research, Clinical Portfolio Management, Medical Affairs, Medical and Commercial Operations, Drug Development, Sales and Marketing settings and Launch Excellence Management. Through these diverse tenures, Jeanette developed a deep understanding on the mechanisms (and challenges) associated with progressing assets through the drug development pipeline to market.

The opportunity in the pharmaceutical industry to hold leadership positions across Australia, New Zealand, Europe, Asia Pacific (mid-size countries) China, and Japan - has afforded Jeanette deep insights into the intricate strategic frameworks required to deliver a strategic vision across multiple regions and stakeholder groups.

As Chief Operating Officer at Noxopharm, Jeanette is tasked to implement an operations framework to deliver the Clinical Development Plan. This includes creating processes for strategic planning and prioritization of projects, resourcing of projects, vendor management, and the implementation of systems and processes for Quality Assurance and Data Risk Management. Jeanette is also involved in Business Development activities for Noxopharm.

Jeanette holds Bachelor of Medical Science (BMedSc) and Master of Science Management (MScM) degrees and operations related qualifications in Portfolio Management (PMO) and Six Sigma Methodologies.

Read more

John Wilkinson 

Chief Scientific Officer - Oncology

BSc Hons, PhD

John brings over 30 years of experience from both pharmaceutical and research settings in Australia and the United Kingdom, with a focus on the development of small molecules to target viruses and cancer. 

John graduated from the University of Portsmouth (BSc Hons) in 1988 and took up a position at the Wellcome Research Laboratories in England and subsequently completed a PhD in HIV-1 Immunovirology from the University of NSW.  An early career in academia, with post-doctoral positions at the Chelsea and Westminster Hospital and Imperial College London in the UK, were followed with an appointment at the Westmead Millennium Institute as a Senior Scientist. His research interests during this time included Drug Discovery and Drug Development, Virology, Oncology and Immunology, translating novel laboratory findings into human clinical trials that resulted in numerous peer-reviewed publications and presentations at both national and international conferences.  Prior to joining Noxopharm, John was the Chief Scientific Officer at Biotron Limited, where he was responsible for the oversight of Biotron's antiviral programs and instrumental in the HIV-1 clinical programs. 

At Noxopharm, John will manage the drug manufacture and supply, support the drug development of novel molecules arising from the company’s drug pipeline, in addition to providing regulatory and clinical support across Noxopharm’s clinical portfolio.

Read more

Olivier Laczka 

Chief Scientific Officer - Inflammation

BSc, MSc, PhD

Dr Laczka obtained a PhD in Biotechnology from the Autonomous University of Barcelona, Spain, in 2009, after completing a master’s degree in applied biotechnology and microbiology and a bachelor’s degree in biological sciences in France. For the first part of his career, Olivier conducted research as an academic, in Spain and Australia, where he was able to successfully develop diagnostic tools toward a wide range of applications, going from medical and food diagnostics to both terrestrial and marine monitoring devices, generating over 25 peer-reviewed research articles and a patent. In 2012, he was awarded the prestigious University of Technology Sydney (UTS) Vice Chancellor’s Postdoctoral Research Fellowship, which enabled him to carry out extensive independent research on the development of novel methods toward the detection of human pathogens.

Dr Laczka’s expertise covers an extensive range of technical skills in microscopy, chemical, electrochemical and optical methods, microbiology, biochemistry, immunology, and molecular biology. In 2015, he joined the Biopharmaceutical industry as a senior research scientist, where he successfully managed and completed therapeutic drug development projects within GLP and cGMP environments, following the current regulatory requirements for early stages of drug development. Dr Laczka’s multidisciplinary background allows him to drive projects covering a wide range of technologies and indications. Throughout his career, Olivier has developed an extensive experience in people and project management, as well as interacting with academic, government, and private entities or individuals, at the international level. His scientific writing experience has also allowed him to attract significant amounts of research funding over the years, through collaborations and partnerships with private entities and government organizations.

Read more

Shawn Van Boheemen 

Chief Financial Officer


Shawn has 30 years' experience in commercial finance leadership positions across a range of manufacturing, service based and financial services industries. He has worked in senior financial positions for a number of both Australian and multinational organisations, including Covance, Unomedical, M.D. Sass and New York Life Insurance. Shawn has a Bachelor of Business Degree in Accounting and Commercial Law, a Master of Commerce Degree with a major in Accounting, is a Fellow of the Australian Society of Certified Practising Accountants and Justice of the Peace in NSW.  Shawn has experience in the contract research and medical devices industries, along with printing/packaging, software and investment management.  His responsibilities have included a number of company secretarial positions, head of compliance, head of information technology, administration and human resources, warehousing and inventory management.

Shawn has experience with both Australian ASX and ASIC reporting, SEC reporting in the U.S., compliance and regulatory affairs matters, intellectual property protection and regulatory and financial reporting both in Australia and the U.S. He spent three years in a global software company as an analyst and Asia Pacific business development manager to further broaden his commercial skillset. He joined Noxopharm Limited in March 2019 and brings a wide range of commercial and financial skills to the organisation.

Read more